Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Jun 2009
Meta AnalysisPopulation pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.
To characterize the population pharmacokinetics of plitidepsin (Aplidin) in cancer patients. ⋯ The integration of phase I/II pharmacokinetic data demonstrated plitidepsin linear elimination from plasma, dose-proportionality up to 8.0 mg/m(2), and time-independent pharmacokinetics. The distribution to red blood cells can be considered linear at doses lower than 5 mg/m(2) administered as 3-h or longer infusion. No clinically relevant covariates were identified as predictors of plitidepsin pharmacokinetics.